MNG332
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.497
- MYC_TARGETS_V1+0.427
- G2M_CHECKPOINT+0.422
- UNFOLDED_PROTEIN_RESPONSE+0.398
- PROTEIN_SECRETION+0.384
- E2F_TARGETS+0.367
- MTORC1_SIGNALING+0.261
- DNA_REPAIR+0.238
- GLYCOLYSIS+0.210
- MITOTIC_SPINDLE+0.171
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.628
- INTERFERON_GAMMA_RESPONSE-0.539
- ALLOGRAFT_REJECTION-0.505
- INFLAMMATORY_RESPONSE-0.408
- APICAL_SURFACE-0.398
- KRAS_SIGNALING_UP-0.372
- IL6_JAK_STAT3_SIGNALING-0.338
- NOTCH_SIGNALING-0.290
- TNFA_SIGNALING_VIA_NFKB-0.276
- KRAS_SIGNALING_DN-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900581 | — | — | 0.891 |
| 2 | C3L-02649 | — | cohortMD1 | 0.890 |
| 3 | MNG534 | — | — | 0.883 |
| 4 | SAMN03290931 | — | — | 0.873 |
| 5 | BS_YBJBSRHV | Embryonal tumors | — | 0.872 |
| 6 | MDT-AP-0134 | Med | Medulloblastoma | 0.870 |
| 7 | MBCProject_4634_T1_RNA | — | E | 0.869 |
| 8 | BS_MV6ASWV9 | ATRT | — | 0.859 |
| 9 | MNG964 | — | — | 0.854 |
| 10 | MNG1195 | — | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.497 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.427 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.422 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.398 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.384 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.367 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.261 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.238 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.171 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.167 | Inavolisib | — uncovered |
| HYPOXIA | 0.166 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.087 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.075 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.054 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.023 | Inavolisib | — uncovered |